SOUTH SAN FRANCISCO, Calif. (AP) _ Veracyte Inc. (VCYT) on Wednesday reported a loss of $8.7 million in its third quarter.
On a per-share basis, the South San Francisco, California-based company said it had a loss of 12 cents.
The results topped Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 24 cents per share.
The molecular diagnostic company posted revenue of $75.6 million in the period, also surpassing Street forecasts. Five analysts surveyed by Zacks expected $67 million.
Veracyte expects full-year revenue in the range of $288 million to $293 million.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a VCYT">Zacks stock report on VCYT at https://www.zacks.com/ap/VCYT